caa a22 4500 469064056 CHVBK 20180323132903.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF02914375 doi (NATIONALLICENCE)springer-10.1007/BF02914375 Levin son Arnold University of Pennsylvania School of Medicine, Philadelphia, PA aut The use of IVIG in neurological disease [Elektronische Daten] [Arnold Levin son] The studies cited herein highlight the potential benefits of IVIG therapy in a group of neurological disorders that are associated with aberrant immune responses. Indeed, all of the disorders discussed, except epilepsy, are associated with autoreactivity. The trials are preliminary and short-term and, except for idiopathic CIDP, uncontrolled. Interpretation of the findings of these uncontrolled studies is complicated by the fact that the natural history of all of these disorders is to show fluctuations, IVIG appears to be a potentially useful and safe agent in the treatment of patients with MG, intractable epilepsy, MS, and CIDP. Its place in the therapeutic approach to these neurological diseases must await the completion of controlled trials. Since other therapeutic modalities have already proven to be useful in several of these disorders, it will be important to determine if IVIG is more efficacious, safer, and more cost-effective. It is also worth considering whether the combination of IVIG and any of these more traditional approaches would provide added therapeutic benefit. The Humana Press Inc, 1992 Clinical Reviews in Allergy Humana Press 10/1-2(1992-03-01), 119-134 0731-8235 10:1-2<119 1992 10 12016 https://doi.org/10.1007/BF02914375 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02914375 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Levin son Arnold University of Pennsylvania School of Medicine, Philadelphia, PA aut NATIONALLICENCE 773 0- Clinical Reviews in Allergy Humana Press 10/1-2(1992-03-01), 119-134 0731-8235 10:1-2<119 1992 10 12016 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer